Dr. Andreadis on Antibody-Drug Conjugates in DLBCL

Video

In Partnership With:

Charalambos (Babis) Andreadis, MD, MSCE, discusses the utility of antibody-drugs conjugates in diffuse large B-cell lymphoma.

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the utility of antibody-drugs conjugates (ADCs) in diffuse large B-cell lymphoma (DLBCL).

ADCs are an emerging treatment modality in DLBCL, says Andreadis. CD30-targeted ADCs have demonstrated efficacy in other diseases like T-cell lymphoma and Hodgkin lymphoma.

In June 2019, the FDA granted an accelerated approval to the CD79b-directed ADC polatuzumab vedotin (Polivy) in combination with bendamustine and rituximab (Rituxan; BR) for the treatment of patients with relapsed/refractory DLBCL who have received ≥2 prior therapies.

The approval was based on data from the phase Ib/II GO29365 study which demonstrated an 40% complete response rate with polatuzumab plus BR versus 18% with BR alone. Historically, these patients did not have many treatment options and weren’t considered for transplant, says Andreadis.

Polatuzumab vedotin is also under investigation as a single agent, in combination with other agents beyond BR, and in different lines of therapy, says Andreadis. Additionally, CD74-targeted ADCs are under investigation.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD